Sanofi details R&D strategy, reports cSCC data for PD-1 inhibitor

Sanofi (Euronext:SAN; NYSE:SNY) highlighted its R&D road map at its analyst meeting Wednesday. The pharma plans to shift its focus to biologics from small molecules, to multi-targeting compounds from mono-targeting ones and to proprietary assets from licensing.

On a conference call Wednesday, CEO Olivier Brandicourt said the company is prioritizing pipeline assets and focusing on improving organizational efficiency across R&D and developing internal proprietary platforms and biological capabilities. The company plans to increase R&D spending by up to €6 billion ($7.1 billion) by 2020, Brandicourt added...